Risk Factors for Mortality and Outcomes in Hematological Malignancy Patients with Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections

References

• Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275–2281.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo LY, Song WQ, Wang Y, Dong F, Liu G. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients. BMC Infect Dis. 2018;18(1):248.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Del Bono V, Trecarichi EM, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect. 2015;21(12):1106 e1101–1108.
   Web of Science ®Google Scholar
• Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099–1106.
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58(9):1274–1283.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Rossolini GM, Piciocchi A, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015;50(2):282–288.
   PubMed Web of Science ®Google Scholar
• Tang Y, Xu C, Xiao H, Wang L, Cheng Q, Li X. Gram-Negative Bacteria Bloodstream Infections in Patients with Hematological Malignancies - The Impact of Pathogen Type and Patterns of Antibiotic Resistance: a Retrospective Cohort Study. Infect Drug Resist. 2021;14:3115–3124.
   Web of Science ®Google Scholar
• Andria N, Henig O, Kotler O, et al. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. J Antimicrob Chemother. 2015;70(11):3146–3153.
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Martino B, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91(11):1076–1081.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wang J, Hu H, et al. Clinical Characteristics and Risk Factors for Bloodstream Infection Due to Carbapenem-Resistant Klebsiella pneumoniae in Patients with Hematologic Malignancies. Infect Drug Resist. 2020;13:3233–3242.
   Web of Science ®Google Scholar
• Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2017;8(4):391–402.
   PubMed Web of Science ®Google Scholar
• Giannella M, Bartoletti M, Conti M, Righi E. Carbapenemase-producing Enterobacteriaceae in transplant patients. J Antimicrob Chemother. 2021;76(Suppl 1):i27–i39.
   Web of Science ®Google Scholar
• Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250–1256.
   PubMed Web of Science ®Google Scholar
• Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis. 2017;17(1):203.
   PubMed Web of Science ®Google Scholar
• Huang ST, Chiang MC, Kuo SC, et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2012;45(5):356–362.
   PubMedGoogle Scholar
• Wang L, Wang Y, Fan X, Tang W, Hu J. Prevalence of Resistant Gram-Negative Bacilli in Bloodstream Infection in Febrile Neutropenia Patients Undergoing Hematopoietic Stem Cell Transplantation: a Single Center Retrospective Cohort Study. Medicine. 2015;94(45):e1931.
   Web of Science ®Google Scholar
• Tofas P, Skiada A, Angelopoulou M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases. Int J Antimicrob Agents. 2016;47(4):335–339.
   PubMed Web of Science ®Google Scholar
• Dai G, Xu Y, Kong H, Xie W, Wang H. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection and associated clinical outcomes. Am J Transl Res. 2021;13(6):7276–7281.
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52(3):1028–1033.
   PubMed Web of Science ®Google Scholar
• Grgic Medic M, Gornik I, Gasparovic V. Hematologic malignancies in the medical intensive care unit–Outcomes and prognostic factors. Hematology. 2015;20(5):247–253.
   PubMed Web of Science ®Google Scholar
• Yeo CD, Kim JW, Kim SC, et al. Prognostic factors in critically ill patients with hematologic malignancies admitted to the intensive care unit. J Crit Care. 2012;27(6):739 e731–736.
   Web of Science ®Google Scholar
• Judickas S, Stasiunaitis R, Zucenka A, Zvirblis T, Serpytis M, Sipylaite J. Outcomes and Risk Factors of Critically Ill Patients with Hematological Malignancy. Prospective Single-Centre Observational Study. Medicina. 2021;57(12):87.
   Web of Science ®Google Scholar
• Bird GT, Farquhar-Smith P, Wigmore T, Potter M, Gruber PC. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. Br J Anaesth. 2012;108(3):452–459.
   Web of Science ®Google Scholar
• Kroschinsky F, Weise M, Illmer T, et al. Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies. Intensive Care Med. 2002;28(9):1294–1300.
   Web of Science ®Google Scholar
• Namendys-Silva SA, Gonzalez-Herrera MO, Garcia-Guillen FJ, Texcocano-Becerra J, Herrera-Gomez A. Outcome of critically ill patients with hematological malignancies. Ann Hematol. 2013;92(5):699–705.
   Web of Science ®Google Scholar
• Liu J, Cheng Q, Yang Q, et al. Prognosis-related factors in intensive care unit (ICU) patients with hematological malignancies: a retrospective cohort analysis in a Chinese population. Hematology. 2015;20(9):494–503.
   PubMed Web of Science ®Google Scholar
• Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents. 1999;11(1):7–12.
   PubMed Web of Science ®Google Scholar
• Lee CC, Wang JL, Lee CH, et al. Age-Related Trends in Adults with Community-Onset Bacteremia. Antimicrob Agents Chemother. 2017;61:12.
   Web of Science ®Google Scholar
• Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003;37(2):230–237.
   PubMed Web of Science ®Google Scholar
• Rhee JY, Kwon KT, Ki HK, et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock. 2009;31(2):146–150.
   PubMed Web of Science ®Google Scholar
• Liu KS, Tong YS, Lee MT, Lin HY, Lu MC. Risk Factors of 30-Day All-Cause Mortality in Patients with Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infection. J Pers Med. 2021;11:7.
   Web of Science ®Google Scholar
• Wang X, Wang Q, Cao B, et al. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant Enterobacteriaceae Bacteremia. Antimicrob Agents Chemother. 2019;63:1.
   Web of Science ®Google Scholar
• Gomez-Simmonds A, Nelson B, Eiras DP, et al. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. Antimicrob Agents Chemother. 2016;60(6):3601–3607.
   PubMed Web of Science ®Google Scholar
• Chen L, Han X, Li Y, Li M. Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales. Antimicrob Agents Chemother. 2021;65(9):e0069821.
   Web of Science ®Google Scholar
• Shen L, Lian C, Zhu B, et al. Bloodstream Infections due to Carbapenem-Resistant Klebsiella pneumoniae: a Single-Center Retrospective Study on Risk Factors and Therapy Options. Microb Drug Resist. 2021;27(2):227–233.
   Web of Science ®Google Scholar
• Xiao T, Zhu Y, Zhang S, et al. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients. J Infect Dis. 2020;221(Suppl 2):S174–S183.
   Web of Science ®Google Scholar
• Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam. Infect Dis Ther. 2020;9(2):291–304.
   Web of Science ®Google Scholar
• Chang H, Wei J, Zhou W, et al. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: clinical impact of carbapenem resistance in a large tertiary hospital of China. J Infect Public Health. 2020;13(5):784–790.
   PubMed Web of Science ®Google Scholar
• Li C, Li Y, Zhao Z, Liu Q, Li B. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital. J Infect Public Health. 2019;12(1):26–31.
   Web of Science ®Google Scholar
• Agyeman AA, Bergen PJ, Rao GG, Nation RL, Landersdorfer CB. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2020;55(1):105833.
   PubMed Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171.
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61:8.
   Web of Science ®Google Scholar
• Hakeam HA, Alsahli H, Albabtain L, Alassaf S, Al Duhailib Z, Althawadi S. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Int J Infect Dis. 2021;109:1–7.
   Web of Science ®Google Scholar
• Fang J, Li H, Zhang M, et al. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant Klebsiella pneumoniae Infections a Retrospective Study. Front Pharmacol. 2021;12:780940.
   Web of Science ®Google Scholar
• Pagano L, Caira M, Trecarichi EM, et al. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis. 2014;20(7):1235–1236.
   PubMed Web of Science ®Google Scholar
• Lalaoui R, Javelle E, Bakour S, Ubeda C, Rolain JM. Infections Due to Carbapenem-Resistant Bacteria in Patients With Hematologic Malignancies. Front Microbiol. 2020;11:1422.
   PubMed Web of Science ®Google Scholar
• Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012;14(2):198–205.
   PubMed Web of Science ®Google Scholar
• Raviv Y, Shitrit D, Amital A, et al. Multidrug-resistant Klebsiella pneumoniae acquisition in lung transplant recipients. Clin Transplant. 2012;26(4):E388–394.
   Web of Science ®Google Scholar
• Mouloudi E, Massa E, Papadopoulos S, et al. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae among intensive care unit patients after orthotopic liver transplantation: risk factors for infection and impact of resistance on outcomes. Transplant Proc. 2014;46(9):3216–3218.
   PubMed Web of Science ®Google Scholar
• Ghafur AK, Vidyalakshmi PR, Kannaian P, Balasubramaniam R. Clinical study of carbapenem sensitive and resistant Gram-negative bacteremia in neutropenic and nonneutropenic patients: the first series from India. Indian J Cancer. 2014;51(4):453–455.
   Web of Science ®Google Scholar
• Freire MP, Pierrotti LC, Filho HH, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients. Eur J Clin Microbiol Infect Dis. 2015;34(2):277–286.
   PubMed Web of Science ®Google Scholar
• Sahitya DSK, Jandiyal A, Jain A, et al. Prevention and management of carbapenem-resistant Enterobacteriaceae in haematopoietic cell transplantation. Ther Adv Infect Dis. 2021;8:20499361211053480.
   Web of Science ®Google Scholar
• Micozzi A, Gentile G, Santilli S, et al. Reduced mortality from KPC-K.pneumoniae bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-K.pneumoniae. BMC Infect Dis. 2021;21(1):1079.
   Web of Science ®Google Scholar